AlphAIAlphAI — Financial news for AI agents
seekingalpha.comOCT 121 min read$MIRM

Mirum's Livmarli meets primary goal in phase 3 trial for itch with rare liver diseases

Mirum Pharmaceuticals (MIRM) announced that its phase 3 trial for Livmarli (maralixibat) in treating severe itching in patients with cholestatic liver diseases met its primary endpoint. The trial involved patients aged six months and older. Mirum reported the results from the EXPAND study, which evaluated the drug's efficacy in improving symptoms.

Original reporting
seekingalpha.com
Published Oct 12, 2026, 2:20 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 12, 2026, 2:29 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefFinancial news
Primary signal
$MIRM
Bullish
high confidence
Mentioned
$MIRM
Relevance
8/10
AlphAI data visualization · based on seekingalpha.com
Decision brief

The 30-second read

$MIRMBullishMed
01

Why it matters

The trial result could accelerate FDA filing and drive near‑term price appreciation.

02

Market read

First‑time positive phase 3 data for a niche indication, likely to move the stock and influence sector sentiment.

03

What to watch

Potential safety signals or competitive pipeline developments not disclosed.

Relevance 8/10Novelty 8/10Timing: today

Background

Mirum is a specialty pharma focused on cholestatic liver disorders; Livmarli is its lead candidate.

Company-level read

Ticker impact

$MIRMBullishHigh confidence
Context

Mirum Pharmaceuticals announced its phase 3 Livmarli trial met the primary endpoint for cholestatic pruritus.

Expected impact

upward pressure as market prices in potential approval and commercial upside

Evidence & confidence

Phase 3 success is a material catalyst for a biotech with no prior data on this indication.

Market effects

Sector

May boost sentiment for other rare‑liver disease therapeutics.

Regional

Limited to US biotech investors; no broader regional effect.

Global

Highlights progress in rare disease drug development globally.

Counterpoint

What could challenge this read

If regulatory hurdles remain high, the stock could face disappointment despite trial success.

Key entities

  • Company
    Mirum Pharmaceuticals

    Developer of Livmarli for cholestatic pruritus.

Read at source← All news

StoryMirum Pharmaceuticals reports positive Phase 3 EXPAND trial results for LIVMARLI

Related articles

OCT 12
$MIRMHighAI 8/10

Baird reiterates Mirum Pharmaceuticals stock rating on trial success

Baird reiterated an Outperform rating and $130 price target for Mirum Pharmaceuticals (MIRM) after positive Phase 3 trial results for maralixibat. The study met primary and secondary endpoints, with 50% of patients having biliary atresia. The company reported 44% revenue growth over the last year and is valued at $5.41 billion. Analysts revised earnings upwards, with price targets ranging from $118 to $195.

investing.com2 min
OCT 12
$MIRMHighAI 9/10

Mirum’s maralixibat meets primary endpoint in liver disease trial

Mirum Pharmaceuticals (MIRM) reported positive Phase 3 trial results for maralixibat in treating cholestatic pruritus in rare liver diseases. The drug met its primary endpoint, showing significant improvement in itch severity and serum bile acids reduction compared to placebo. Mirum plans to submit a supplemental New Drug Application in the U.S. in early 2027.

investing.com2 min
OCT 12
$MIRMMedAI 9/10

Mirum Pharmaceuticals, Inc. (MIRM) Phase 3 EXPAND Meets Primary, All Secondary Endpoints

Mirum Pharmaceuticals (MIRM) announced its Phase 3 EXPAND study of LIVMARLI met primary and secondary endpoints, including biliary atresia analyses, with no new safety concerns. The company plans a U.S. supplemental New Drug Application in H1 2027. According to the company, this extends LIVMARLI's potential beyond ALGS and PFIC to other ultra-rare cholestatic pruritus conditions.

tradingview.com1 min